about our Partner
For over 15 years the Jeffrey Pride Foundation has chosen to direct the funds we raise to the Children’s Oncology Group (COG) because it is the world’s largest organization devoted exclusively to childhood and adolescent cancer research with nearly 100 clinical trials in progress at any given time.
COG’s collaborative research is done by over 9,000 experts at more than 200 leading children’s hospitals across North America, Australia, New Zealand and Europe. In the Chicago area alone COG network hospitals include Ann and Robert H. Lurie Children's Hospital, University of Chicago Comprehensive Cancer Center, Loyola University Medical Center, University of Illinois, and Advocate Children’s Hospitals in Park Ridge and Oak Lawn. It is the work of COG that will cure pediatric cancers.
The COG chairman, Dr. Peter Adamson, is our medical advisor. With his guidance we determine what projects and studies will have the greatest impact in finding cures. He provides us with feedback on the progress of these studies regularly so we may report back to our donors. We want our donors to know exactly what their money is accomplishing!
As the chair of the Children's Oncology Group (COG), a group of more than 200 leading children’s hospitals, universities, and cancer centers that brings together more than 9,000 international experts in childhood cancer, I am in frequent contact with leading researchers around the world.
There are a wide range of opportunities focusing on improving the outcome for children with cancer, and we are hard at work trying to speed the timeline so the most promising new therapies can move forward. We are working on creating better pathways for disease-targeted therapies for children with cancer, and are focusing our efforts on transforming how new discoveries can move from the bench to the bedside, a process called translational research.
Before becoming chair of the COG, I led a group of 21 institutions that performed the initial evaluation of new drugs for children with cancer. During the more than eight years that I led the COG Phase 1 Consortium, we conducted numerous phase I studies. These studies are the first clinical trials of new anticancer drugs in children whose cancer has recurred despite best-known treatments. I thus have direct knowledge of the investigational new drug trials being conducted not only at Children's Hospital, but at centers worldwide. This allows me to serve as a resource on experimental cancer treatment for Children's Hospital clinicians. For the child whose cancer has recurred, these are the kinds of trials they often seek out.